MCID: PMS001
MIFTS: 58

Poems Syndrome

Categories: Blood diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Poems Syndrome

MalaCards integrated aliases for Poems Syndrome:

Name: Poems Syndrome 11 19 58 75 28 53 43 14 16 71
Crow-Fukase Syndrome 19 58 75
Osteosclerotic Myeloma 58 71
Polyneuropathy, Organomegaly, Endocrinopathy, M Protein, and Skin Changes Syndrome 19
Polyneuropathy-Endocrinopathy-Plasma Cell Dyscrasia Syndrome 58
Polyneuropathy Organomegaly 19
Takatsuki Syndrome 58
Pep Syndrome 58

Characteristics:


Prevelance:

1-9/1000000 (Japan) 58

Age Of Onset:

Adult,Elderly 58

Age Of Death:

adult,elderly,normal life expectancy 58

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare haematological diseases


Summaries for Poems Syndrome

GARD: 19 POEMS syndrome is a rare, mulitisystem disorder. POEMS stands for the disorder's features, which may include Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin changes. Signs and symptoms may include progressive sensorimotor polyneuropathy; enlarged liver, spleen, and/or lymph nodes; a disorder of the endocrine glands (often with multiple abnormalities); a monoclonal plasma cell proliferative disorder; and darkening of the skin (hyperpigmentation). Various other symptoms may also occur and may vary among affected people. The underlying cause of the disorder is not well understood.

MalaCards based summary: Poems Syndrome, also known as crow-fukase syndrome, is related to glomeruloid hemangioma and castleman disease. An important gene associated with Poems Syndrome is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dexamethasone acetate and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include skin, bone and spleen, and related phenotypes are polyneuropathy and visceromegaly

Orphanet: 58 POEMS syndrome is a paraneoplastic syndrome characterized by polyradiculoneuropathy (P), organomegaly (O), endocrinopathy (E), clonal plasma cell disorder (M), and skin changes (S). Other features include papilledema, extravascular volume overload, sclerotic bone lesions, thrombocytosis/erythrocytosis, and elevated VEGF levels.

Disease Ontology: 11 A blood protein disease that is characterized by polyneuropathy, oranomegaly, endocrinopathy, monoclonal gammopathy, and skin changes, especially hyperpigmentation.

Wikipedia: 75 POEMS syndrome (also termed osteosclerotic myeloma, Crow-Fukase syndrome, Takatsuki disease, or PEP... more...

Related Diseases for Poems Syndrome

Diseases related to Poems Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 941)
# Related Disease Score Top Affiliating Genes
1 glomeruloid hemangioma 32.2 VEGFA MYOM2
2 castleman disease 31.6 VEGFA MYOM2 IL6
3 papilledema 31.3 VEGFA MYOM2 IL6
4 plasmacytoma 31.2 VEGFA IL6 IL2
5 osteosclerotic myeloma 31.1 VEGFA MYOM2 IL6 IL1B
6 demyelinating polyneuropathy 31.1 TNF MYOM2 IL6
7 thrombocytosis 31.0 IL6 IL1B EPO CSF3
8 monoclonal gammopathy of uncertain significance 30.8 TNFSF11 MYOM2 IL6
9 multicentric castleman disease 30.8 VEGFA MYOM2 IL6
10 spinal cord disease 30.7 VEGFA TNF IL6
11 amyloidosis 30.6 TNF MYOM2 IL6 IL1B
12 intracranial hypertension 30.6 TNF IL6 IL1B
13 hemangioma 30.6 VEGFA IL6 FGF2 ANGPT2
14 macular dystrophy, dominant cystoid 30.5 VEGFA TNF IL6
15 stroke, ischemic 30.5 VEGFA TNF IL6 IL1B
16 carotid artery occlusion 30.5 VEGFA IL1B EPO
17 cryoglobulinemia 30.4 TNF IL6 IL1B
18 optic nerve disease 30.3 VEGFA TNF IL6 IL1B
19 pulmonary hypertension 30.3 VEGFA TNF IL6 HGF FGF2
20 paraneoplastic syndromes 30.1 IL6 CSF3
21 kaposi sarcoma 30.1 VEGFA IL6 IL1B FGF2
22 anemia, autoimmune hemolytic 30.1 IL6 IL2 EPO
23 pericardial effusion 30.1 VEGFA TNF IL6 FGF2
24 alopecia 30.1 TNF IL6 IL2 IL1B
25 endogenous depression 30.0 TNF IL6 IL1B
26 ileus 29.9 TNF IL6 IL1B
27 thyroiditis 29.9 TNF IL6 IL2 IL1B
28 lyme disease 29.9 TNF IL6 IL1B
29 toxic encephalopathy 29.9 TNF IL6 IL1B
30 bone resorption disease 29.9 TNFSF11 TNF IL6 IL1B
31 vasculitis 29.8 TNF PTX3 IL6 IL1B CXCL8
32 systemic scleroderma 29.8 VEGFA TNF IL6 IL2 IL1B CXCL8
33 aortitis 29.8 TNF IL6 IL1B CSF3
34 polycythemia vera 29.8 VEGFA TNF IL6 EPO CSF3
35 varicose veins 29.8 VEGFA TNF IL6 CXCL8
36 kidney disease 29.7 VEGFA TNFSF11 TNF IL6 HGF EPO
37 premature menopause 29.7 VEGFA TNFSF11 TNF IL6
38 orchitis 29.7 TNF IL6 IL2 IL1B
39 blood group, globoside system 29.7 VEGFA TNF IL6 IL1B CXCL8
40 arthropathy 29.7 TNFSF11 TNF IL6 IL1B
41 capillary leak syndrome 29.7 VEGFA IL6 IL2 CXCL8
42 aplastic anemia 29.7 TNF IL6 IL1B EPO CSF3
43 pneumonia 29.7 TNF IL6 IL1B CXCL8 CSF3
44 proctitis 29.7 VEGFA TNF FGF2
45 essential thrombocythemia 29.7 IL6 FGF2 EPO CSF3
46 bell's palsy 29.7 TNF IL6
47 myositis 29.6 TNF IL6 IL1B
48 congestive heart failure 29.6 VEGFA TNF IL6 IL1B EPO ANGPT2
49 myeloma, multiple 29.6 VEGFA TNFSF11 MYOM2 IL6 IL2 IL1B
50 retinal artery occlusion 29.6 VEGFA IL6 CXCL8

Graphical network of the top 20 diseases related to Poems Syndrome:



Diseases related to Poems Syndrome

Symptoms & Phenotypes for Poems Syndrome

Human phenotypes related to Poems Syndrome:

58 30 (show all 48)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 polyneuropathy 58 30 Obligate (100%) Obligate (100%)
HP:0001271
2 visceromegaly 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003271
3 hypogonadism 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000135
4 lymphoproliferative disorder 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0005523
5 abnormality of skin physiology 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0011122
6 increased circulating antibody level 30 Hallmark (90%) HP:0010702
7 diabetes mellitus 58 30 Frequent (33%) Frequent (79-30%)
HP:0000819
8 hypothyroidism 58 30 Frequent (33%) Frequent (79-30%)
HP:0000821
9 fatigue 58 30 Frequent (33%) Frequent (79-30%)
HP:0012378
10 ascites 58 30 Frequent (33%) Frequent (79-30%)
HP:0001541
11 areflexia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001284
12 paresthesia 58 30 Frequent (33%) Frequent (79-30%)
HP:0003401
13 hemangioma 58 30 Frequent (33%) Frequent (79-30%)
HP:0001028
14 weight loss 58 30 Frequent (33%) Frequent (79-30%)
HP:0001824
15 gynecomastia 58 30 Frequent (33%) Frequent (79-30%)
HP:0000771
16 erectile dysfunction 58 30 Frequent (33%) Frequent (79-30%)
HP:0100639
17 pulmonary arterial hypertension 58 30 Frequent (33%) Frequent (79-30%)
HP:0002092
18 primary adrenal insufficiency 58 30 Frequent (33%) Frequent (79-30%)
HP:0008207
19 thickened skin 58 30 Frequent (33%) Frequent (79-30%)
HP:0001072
20 pleural effusion 58 30 Frequent (33%) Frequent (79-30%)
HP:0002202
21 lymphadenopathy 58 30 Frequent (33%) Frequent (79-30%)
HP:0002716
22 pericardial effusion 58 30 Frequent (33%) Frequent (79-30%)
HP:0001698
23 hypertrichosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0000998
24 leukonychia 58 30 Frequent (33%) Frequent (79-30%)
HP:0001820
25 hyperpigmentation of the skin 58 30 Frequent (33%) Frequent (79-30%)
HP:0000953
26 pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0012531
27 thrombocytosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0001894
28 sclerosis of hand bone 58 30 Frequent (33%) Frequent (79-30%)
HP:0004054
29 papilledema 58 30 Frequent (33%) Frequent (79-30%)
HP:0001085
30 sclerosis of skull base 58 30 Frequent (33%) Frequent (79-30%)
HP:0002694
31 sclerotic vertebral endplates 58 30 Frequent (33%) Frequent (79-30%)
HP:0004576
32 metaphyseal sclerosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0004979
33 clubbing of fingers 58 30 Frequent (33%) Frequent (79-30%)
HP:0100759
34 sclerosis of foot bone 58 30 Frequent (33%) Frequent (79-30%)
HP:0100925
35 acrocyanosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001063
36 venous thrombosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0004936
37 lipodystrophy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0009125
38 respiratory insufficiency due to muscle weakness 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002747
39 arterial thrombosis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0004420
40 polycythemia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001901
41 hyperesthesia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100963
42 increased circulating prolactin concentration 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000870
43 restrictive ventilatory defect 30 Occasional (7.5%) HP:0002091
44 muscle weakness 58 Frequent (79-30%)
45 abnormality of the endocrine system 58 Very frequent (99-80%)
46 increased antibody level in blood 58 Very frequent (99-80%)
47 edema 58 Frequent (79-30%)
48 restrictive deficit on pulmonary function testing 58 Occasional (29-5%)

MGI Mouse Phenotypes related to Poems Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.02 ANGPT2 EPO FGF2 HGF IL1B IL2
2 immune system MP:0005387 10.02 ANGPT2 CSF3 EPO IL1B IL2 IL6
3 neoplasm MP:0002006 9.95 FGF2 IL1B IL2 IL6 TNF TNFSF11
4 respiratory system MP:0005388 9.86 ANGPT2 EPO IL2 IL6 PTX3 TNF
5 vision/eye MP:0005391 9.76 ANGPT2 FGF2 IL2 IL6 MYOM2 TNF
6 hematopoietic system MP:0005397 9.73 ANGPT2 CSF3 EPO FGF2 HGF IL1B
7 integument MP:0010771 9.23 ANGPT2 CSF3 IL1B IL6 MYOM2 TNF

Drugs & Therapeutics for Poems Syndrome

Drugs for Poems Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2 1177-87-3 3680
2
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 3003 5743
3
Lenalidomide Approved Phase 2 191732-72-6 216326
4
Daratumumab Approved Phase 2 945721-28-8
5 Gastrointestinal Agents Phase 2
6 glucocorticoids Phase 2
7 Angiogenesis Inhibitors Phase 2
8 Antineoplastic Agents, Hormonal Phase 2
9 Antiemetics Phase 2
10 BB 1101 Phase 2
11
protease inhibitors Phase 2
12 Hormones Phase 2
13 Hormone Antagonists Phase 2
14 HIV Protease Inhibitors Phase 2
15 Anti-Inflammatory Agents Phase 2
16 Immunologic Factors Phase 2
17 Antibodies, Monoclonal Phase 2
18 Antibodies Phase 2
19 Immunoglobulins Phase 2
20
Sodium citrate Approved, Investigational Early Phase 1 68-04-2 23431961
21
Ixazomib Approved, Investigational Early Phase 1 1072833-77-2 25183872
22
Ichthammol Approved Early Phase 1 8029-68-3
23
Citric acid Approved, Nutraceutical, Vet_approved Early Phase 1 77-92-9 311
24
Glycine Approved, Nutraceutical, Vet_approved Early Phase 1 56-40-6 750
25 Dermatologic Agents Early Phase 1
26 Citrate Early Phase 1
27 Neurotransmitter Agents Early Phase 1
28 Hemostatics
29 Chrysarobin

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Evaluation of Efficacy and Safety of Lenalidomide (Revlimid®) in Patients With POEMS Syndrome Unknown status NCT00971685 Phase 2 Lenalidomide and dexamethasone
2 Single Arm Open-label Trial to Investigate the Efficacy and Safety of Lenlidomide as a Treatment for Recurrent or Refractory Crow-Fukase (POEMS) Syndrome Completed NCT02193698 Phase 2 Lenalidomide+Dexamethasone
3 An Open-label Phase II Study to Determine the Efficacy and Safety of Lenalidomide Plus Dexamethasone (LDex) in Patients With Newly Diagnosed POEMS Syndrome Completed NCT01816620 Phase 2 Lenalidomide, Dexamethasone
4 Phase II Trial With Lenalidomide-Dexamethasone Combination in the Treatment of POEMS Syndrome. Completed NCT01639898 Phase 2 Lenalidomide and dexamethasone
5 A Phase II Trial for the Treatment of POEMS Syndrome With Daratumumab Recruiting NCT04396496 Phase 2 Daratumumab Injection
6 A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis Recruiting NCT05263817 Early Phase 1
7 Registry for Adults With Plasma Cell Disorders (PCD's) Recruiting NCT03717844
8 A Prospective Cohort Study of Patients With Plasma Cell Disorders (PCDs) in PKUFH Recruiting NCT05283993
9 Ixazomib, Lenalidomide, and Dexamethasone for Patients With POEMS Syndrome Active, not recruiting NCT02921893 Early Phase 1 Dexamethasone;Ixazomib Citrate;Lenalidomide
10 Prospective, Randomized, Single Center Study to Evaluate Efficacy of Red Dichromatic Imaging (RDI) in Achieving Hemostasis During Peroral Endoscopic Myotomy Using GF 1500 UGI Scope: A Pilot Study Not yet recruiting NCT05476458

Search NIH Clinical Center for Poems Syndrome

Cochrane evidence based reviews: poems syndrome

Genetic Tests for Poems Syndrome

Genetic tests related to Poems Syndrome:

# Genetic test Affiliating Genes
1 Poems Syndrome 28

Anatomical Context for Poems Syndrome

Organs/tissues related to Poems Syndrome:

MalaCards : Skin, Bone, Spleen, Liver, T Cells, Endothelial, Lymph Node

Publications for Poems Syndrome

Articles related to Poems Syndrome:

(show top 50) (show all 1349)
# Title Authors PMID Year
1
[Advances and perspectives in treatment for refractory neuropathies with special reference to immune-mediated neuropathies and Crow-Fukase syndrome]. 53 62
20411803 2010
2
POEMS syndrome with idiopathic portal hypertension: autopsy case and review of the literature. 53 62
20403034 2010
3
[Crow-Fukase (POEMS) syndrome]. 53 62
20420180 2010
4
POEMS syndrome complicated by follicular lymphoma. 53 62
20009437 2009
5
Relapse of POEMS syndrome without increased level of VEGF. 53 62
19720532 2009
6
Relapse of polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome without increased level of vascular endothelial growth factor following successful autologous peripheral blood stem cell transplantation. 53 62
19269178 2009
7
Serum VEGF levels in POEMS syndrome and in immune-mediated neuropathies. 53 62
19289745 2009
8
Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. 53 62
18469028 2008
9
Discrepancy between disease activity and levels of vascular endothelial growth factor in a patient with POEMS syndrome successfully treated with autologous stem-cell transplantation. 53 62
18660839 2008
10
Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. 53 62
18843731 2008
11
[New strategy of treatment for POEMS syndrome--autologous peripheral blood stem cell transplantation and thalidomide therapy]. 53 62
18567358 2008
12
[Crow-Fukase syndrome and VEGF]. 53 62
18567356 2008
13
Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. 53 62
18221391 2008
14
VEGF and osteosclerosis in POEMS syndrome. 53 62
18172647 2008
15
Optic disc edema, cystoid macular edema, and elevated vascular endothelial growth factor in a patient with POEMS syndrome. 53 62
17895817 2007
16
[POEMS syndrome presenting with transient immunoglobulin isotype switching after successful treatment with autologous peripheral blood stem cell transplantation]. 53 62
17867301 2007
17
Expression of vascular endothelial growth factor by plasma cells in the sclerotic bone lesion of a patient with POEMS syndrome. 53 62
17277913 2007
18
Increased expression of vascular endothelial growth factor and its receptor, Flt-1, in glomeruloid haemangioma associated with Crow-Fukase syndrome. 53 62
17309484 2007
19
[Blood cytokine levels as a clinical laboratory test]. 53 62
17441472 2007
20
Recurrent Crow-Fukase syndrome associated with increased serum levels of vascular endothelial growth factor: a case report and review of the literature. 53 62
17077605 2006
21
Successful treatment of a patient with POEMS syndrome by tandem high-dose chemotherapy with autologous CD34+ purged stem cell rescue. 53 62
16926143 2006
22
Angiogenetic factors and biochemical markers of bone metabolism in POEMS syndrome treated with high-dose therapy and autologous stem cell support. 53 62
16879774 2006
23
Marked recovery of severe renal lesions in POEMS syndrome with high-dose melphalan therapy supported by autologous blood stem cell transplantation. 53 62
16564945 2006
24
Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. 53 62
15975949 2005
25
A case of POEMS syndrome with cystoid macular edema. 53 62
15767082 2005
26
[Highly concentrated vascular endothelial growth factor in Crow-Fukase syndrome with high output heart failure: a case report]. 53 62
15768610 2005
27
POEMS syndrome demonstrating VEGF decrease by ticlopidine. 53 62
15609708 2004
28
POEMS syndrome and VEGF. 53 62
15609693 2004
29
No nephropathy in Type 2 diabetic patient with POEMS syndrome with an elevated plasma VEGF. 53 62
15008843 2004
30
Predictive value of serial platelet count and VEGF determination for the management of DIC in the Crow-Fukase (POEMS) syndrome. 53 62
14714967 2003
31
Multiple vascular abnormalities and a paradoxical combination of vitamin B12 deficiency and thrombocytosis in a case with POEMS syndrome. 53 62
14673584 2003
32
[A case of anaphylactoid shock occurring immediately after the initiation of second intravenous administration of high-dose immunoglobulin (IVIg) in a patient with Crow-Fukase syndrome]. 53 62
14503355 2003
33
POEMS syndrome associated with ischemic stroke. 53 62
12756139 2003
34
[A case of Crow-Fukase syndrome with extramedullary plasmacytoma: marked clinical deterioration following a biopsy to plasmacytoma]. 53 62
12884826 2003
35
Diurnal fluctuation of edema synchronized with plasma VEGF concentration in a patient with POEMS syndrome. 53 62
12521215 2002
36
Crow-Fukase syndrome associated with high-output heart failure. 53 62
12211533 2002
37
[POEMS syndrome with increased vascular endothelial growth factor (VEGF) and multiple osteosclerotic lesion]. 53 62
12170754 2002
38
An autopsy case of POEMS syndrome with a high level of IL-6 and VEGF in the serum and ascitic fluid. 53 62
11929188 2002
39
[POEMS syndrome with increased vascular endothelial growth factor (VEGF)]. 53 62
11917504 2002
40
[Vascular endothelial growth factor and Crow-Fukase syndrome]. 53 62
12235821 2001
41
[A case of polyneuropathy associated with increased levels of vascular endotherial growth factor (VEGF) insera]. 53 62
11993185 2001
42
A case of POEMS syndrome with high concentrations of interleukin-6 in pericardial fluid. 53 62
11489068 2001
43
Increased serum level of vascular endothelial growth factor in Crow-Fukase syndrome. 53 62
11720194 2001
44
Circulating levels of MMP-1, -2, -3, -9, and TIMP-1 are increased in POEMS syndrome. 53 62
11274326 2001
45
[A patient with Crow-Fukase syndrome associated with pulmonary plasmacytoma]. 53 62
11481854 2001
46
VEGF is causative for pulmonary hypertension in a patient with Crow-Fukase (POEMS) syndrome. 53 62
11197800 2000
47
Highly concentrated vascular endothelial growth factor in platelets in Crow-Fukase syndrome. 53 62
10882999 2000
48
[POEMS syndrome revealed by a scleroderma-like skin thickening]. 53 62
10717569 2000
49
Growth factors and proinflammatory cytokines in the renal involvement of POEMS syndrome. 53 62
10516342 1999
50
A spectrum of clinicopathological features of nephropathy associated with POEMS syndrome. 53 62
10528660 1999

Variations for Poems Syndrome

Expression for Poems Syndrome

Search GEO for disease gene expression data for Poems Syndrome.

Pathways for Poems Syndrome

Pathways related to Poems Syndrome according to GeneCards Suite gene sharing:

(show top 50) (show all 71)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.94 CSF3 CXCL8 FGF2 HGF IL1B IL2
2
Show member pathways
13.78 ANGPT2 CSF3 CXCL8 FGF2 HGF IL1B
3 13.74 CXCL8 EPO FGF2 HGF IL2 IL6
4
Show member pathways
13.57 VEGFA TNFSF11 TNF IL6 IL2 IL1B
5
Show member pathways
13.51 VEGFA TNF IL6 IL2 IL1B HGF
6
Show member pathways
13.44 VEGFA TNF IL6 IL2 IL1B HGF
7
Show member pathways
13.36 ANGPT2 CSF3 CXCL8 FGF2 HGF IL1B
8
Show member pathways
13.25 VEGFA TNF IL6 IL2 HGF FGF2
9
Show member pathways
13.25 VEGFA TNFSF11 TNF IL6 IL2 IL1B
10
Show member pathways
13.22 ANGPT2 CSF3 CXCL8 FGF2 HGF IL1B
11
Show member pathways
12.96 VEGFA IL6 IL2 HGF FGF2 EPO
12
Show member pathways
12.83 TNF IL6 IL2 IL1B CXCL8
13
Show member pathways
12.74 TNF IL6 IL2 IL1B HGF FGF2
14 12.71 VEGFA IL6 IL1B HGF FGF2 CSF3
15
Show member pathways
12.64 CXCL8 EPO FGF2 HGF IL1B IL2
16
Show member pathways
12.63 ANGPT2 FGF2 IL1B IL2 IL6 TNF
17
Show member pathways
12.59 TNF IL6 IL1B CXCL8
18 12.55 IL1B IL2 TNF TNFSF11
19
Show member pathways
12.51 TNF IL6 IL1B CXCL8
20
Show member pathways
12.41 TNF IL6 IL1B CXCL8
21
Show member pathways
12.35 TNF IL6 IL1B FGF2 CXCL8
22
Show member pathways
12.28 TNF IL6 CXCL8 CSF3
23 12.23 VEGFA TNF IL6 IL1B CXCL8
24 12.13 TNF IL6 IL1B FGF2
25 12.1 VEGFA IL6 HGF FGF2
26 12.07 TNF IL6 IL2 EPO CSF3
27 12.06 TNF IL6 IL2 IL1B CXCL8
28
Show member pathways
11.97 TNF IL6 IL2 IL1B
29 11.96 VEGFA IL2 CXCL8
30 11.95 CXCL8 FGF2 IL6 VEGFA
31 11.95 VEGFA TNF IL2 IL1B CXCL8
32 11.93 IL6 IL1B CXCL8
33
Show member pathways
11.87 IL6 CXCL8 CSF3
34 11.85 HGF FGF2 ANGPT2
35 11.82 TNF IL6 IL2 IL1B
36 11.8 TNF IL2 IL1B
37 11.78 IL6 IL2 CXCL8
38 11.75 TNF IL6 IL2
39 11.73 IL6 IL2 IL1B
40 11.73 IL6 IL2 CXCL8
41 11.73 TNFSF11 TNF IL6 IL1B
42 11.73 VEGFA TNF IL6 IL1B HGF FGF2
43 11.72 IL6 IL2 HGF FGF2
44 11.72 CXCL8 HGF IL1B IL6 TNF VEGFA
45
Show member pathways
11.71 TNF IL2 CXCL8
46 11.67 CXCL8 IL6 TNF
47
Show member pathways
11.64 TNF IL6 IL2
48 11.61 VEGFA IL6 CXCL8
49 11.6 VEGFA IL6 IL2
50
Show member pathways
11.6 VEGFA TNF IL6 IL2 IL1B CXCL8

GO Terms for Poems Syndrome

Cellular components related to Poems Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.07 VEGFA TNFSF11 TNF PTX3 IL6 IL2
2 extracellular space GO:0005615 9.74 ANGPT2 CSF3 CXCL8 EPO FGF2 HGF

Biological processes related to Poems Syndrome according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.5 CSF3 FGF2 HGF IL1B IL2 IL6
2 signal transduction GO:0007165 10.46 VEGFA TNF IL6 IL1B FGF2 EPO
3 inflammatory response GO:0006954 10.39 TNF PTX3 IL6 IL1B CXCL8
4 positive regulation of cell population proliferation GO:0008284 10.38 VEGFA IL6 IL2 IL1B FGF2 EPO
5 positive regulation of gene expression GO:0010628 10.36 VEGFA TNFSF11 TNF IL6 IL1B FGF2
6 negative regulation of apoptotic process GO:0043066 10.32 EPO HGF IL2 IL6 TNF VEGFA
7 negative regulation of cell population proliferation GO:0008285 10.3 TNF IL6 IL1B FGF2 CXCL8
8 response to hypoxia GO:0001666 10.28 ANGPT2 EPO TNF VEGFA
9 cytokine-mediated signaling pathway GO:0019221 10.26 TNFSF11 IL6 IL1B CSF3
10 cellular response to lipopolysaccharide GO:0071222 10.22 CSF3 CXCL8 IL1B IL6 TNF
11 immune response GO:0006955 10.22 TNFSF11 TNF IL6 IL2 IL1B CXCL8
12 positive regulation of NF-kappaB transcription factor activity GO:0051092 10.21 TNFSF11 TNF IL6 IL1B
13 positive regulation of MAPK cascade GO:0043410 10.21 VEGFA TNF IL6 HGF FGF2
14 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 10.19 CSF3 HGF IL6 VEGFA
15 positive regulation of peptidyl-serine phosphorylation GO:0033138 10.19 VEGFA TNF IL6 CSF3
16 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 10.18 VEGFA TNF HGF
17 positive regulation of interleukin-8 production GO:0032757 10.17 IL1B IL6 TNF
18 I-kappaB kinase/NF-kappaB signaling GO:0007249 10.16 IL1B TNF TNFSF11
19 JNK cascade GO:0007254 10.16 TNFSF11 TNF IL1B
20 positive regulation of DNA-binding transcription factor activity GO:0051091 10.16 CSF3 IL1B IL6 TNF TNFSF11
21 positive regulation of phagocytosis GO:0050766 10.15 TNF PTX3 IL1B
22 positive regulation of cell division GO:0051781 10.15 VEGFA IL1B FGF2
23 response to activity GO:0014823 10.14 ANGPT2 IL6 TNF
24 regulation of insulin secretion GO:0050796 10.14 IL1B IL6 TNF
25 protein kinase B signaling GO:0043491 10.13 FGF2 IL1B TNF TNFSF11
26 positive chemotaxis GO:0050918 10.12 FGF2 HGF VEGFA
27 positive regulation of nitric oxide biosynthetic process GO:0045429 10.11 TNF PTX3 IL1B
28 positive regulation of protein phosphorylation GO:0001934 10.11 FGF2 HGF IL1B IL2 TNF VEGFA
29 positive regulation of T cell proliferation GO:0042102 10.09 IL6 IL2 IL1B
30 positive regulation of protein kinase B signaling GO:0051897 10.09 VEGFA TNFSF11 TNF FGF2 CSF3
31 positive regulation of smooth muscle cell proliferation GO:0048661 10.08 TNF IL6 FGF2
32 negative regulation of blood vessel endothelial cell migration GO:0043537 10.08 TNF FGF2 ANGPT2
33 negative regulation of neurogenesis GO:0050768 10.08 TNF IL6 IL1B
34 positive regulation of glial cell proliferation GO:0060252 10.05 TNF IL6 IL1B
35 positive regulation of chemokine production GO:0032722 10.04 TNF IL6 IL1B
36 regulation of establishment of endothelial barrier GO:1903140 10.01 TNF IL1B
37 negative regulation of lipid storage GO:0010888 10 TNF IL6
38 paracrine signaling GO:0038001 9.99 TNFSF11 FGF2
39 positive regulation of neuroinflammatory response GO:0150078 9.97 IL1B IL6 TNF
40 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.97 VEGFA TNF HGF FGF2 CSF3
41 positive regulation of MAP kinase activity GO:0043406 9.96 VEGFA TNFSF11 TNF IL1B FGF2
42 positive regulation of fever generation GO:0031622 9.95 TNF IL1B
43 sequestering of triglyceride GO:0030730 9.93 TNF IL1B
44 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.92 TNF IL1B
45 vascular endothelial growth factor production GO:0010573 9.88 TNF IL6 IL1B
46 positive regulation of epithelial tube formation GO:1905278 9.81 VEGFA FGF2
47 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.81 EPO IL2 IL6 TNF VEGFA
48 positive regulation of angiogenesis GO:0045766 9.73 VEGFA IL1B HGF FGF2 CXCL8 ANGPT2
49 positive regulation of DNA biosynthetic process GO:2000573 9.17 VEGFA TNF HGF FGF2

Molecular functions related to Poems Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.76 TNFSF11 TNF IL6 HGF CSF3 ANGPT2
2 chemoattractant activity GO:0042056 9.73 VEGFA HGF FGF2
3 growth factor activity GO:0008083 9.73 CSF3 FGF2 HGF IL2 IL6 VEGFA
4 cytokine activity GO:0005125 9.6 VEGFA TNFSF11 TNF IL6 IL2 IL1B

Sources for Poems Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 24-Oct-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....